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Abstract
Obesity,amajorriskfactorforendometrialcancer,isalow-gradeinﬂammatorystatecharacterized
by elevated concentrations of cytokines and acute phase reactants. The current study had two
aims: ﬁrst to investigate the associations of C-reactive protein (CRP), interleukin 6 (IL6), and IL1
receptor antagonist (IL1Ra) with endometrial cancer risk and second to examine to which
extent these markers can inﬂuence the association between obesity and endometrial cancer.
We conducted a case–control study, nested within the European Prospective Investigation into
CancerandNutrition,whichcomprised305incidentcasesofendometrialcancerand574matched
controls. CRP, IL6, and IL1Ra were measured in prospectively collected blood specimens by
immunoassays. Data were analyzed using conditional logistic regression. All statistical tests were
two-sided, and P values !0.05 were considered statistically signiﬁcant. We observed a signiﬁcant
increase in risk of endometrial cancer with elevated levels of CRP (odds ratio (OR) for top versus
bottomquartile:1.58,95%conﬁdenceinterval(CI):1.03–2.41,PtrendZ0.02),IL6(ORfortopversus
bottom quartile: 1.66, 95% CI: 1.08–2.54, PtrendZ0.008), and IL1Ra (OR for top versus bottom
quartile: 1.82, 95% CI: 1.22–2.73, PtrendZ0.004). After adjustment for body mass index (BMI), the
estimates were strongly reduced and became non-signiﬁcant. The association between BMI and
endometrial cancer was also substantially attenuated (w10–20%) after adjustment for
inﬂammatory markers, even when the effects of C-peptide or estrone had already been taken
into account. We provided epidemiological evidence that chronic inﬂammation might mediate the
associationbetweenobesityandendometrialcancerandthatendometrialcarcinogenesiscouldbe
promoted by an inﬂammatory milieu.
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Introduction
Excess body weight is one of the strongest risk factors
for endometrial cancer and accounts for about 50%
of the cases in Europe and in the USA (International
Agency for Research on Cancer (IARC) 2002, Calle &
Kaaks 2004, World Cancer Research Fund/American
Institute for Cancer Research 2007). Obese women
(body mass index (BMI) O30 kg/m
2) have a threefold
increased risk of developing endometrial cancer
compared to normal weight women (Calle & Kaaks
2004, Reeves et al. 2007).
Several biological mechanisms could mediate the
association between obesity and endometrial cancer
risk. In postmenopausal women, excess weight leads,
through peripheral conversion of androgens, to
increased circulating bioavailable estrogens which in
turn, when not counterbalanced by progesterone,
increases the mitogenic activity of endometrial cells
(Key & Pike 1988). In premenopausal women, obesity
has been associated with the development of polycystic
ovary syndrome, a disease that affects 4–8% of
women and is characterized by ovarian hyperandro-
genism, anovulation, and progesterone deﬁciency
(Ehrmann et al.1 9 9 5 , Franks 1995). Obesity-associated
hyperinsulinemia might also play an important role
in endometrial carcinogenesis, in both pre and post-
menopausal women, either directly, by stimulating
endometrial cell proliferation, or indirectly, through the
sexsteroidandtheinsulin-like growthfactor1pathways
(Kaaks et al.2 0 0 2 ).
More recently, it has been proposed that other
adiposity-related factors such as cytokines and adipo-
kines might contribute to endometrial cancer initiation
and progression and to the obesity-related increase in
risk (Modugno et al. 2005). Excess body weight is
associated with a systemic low-grade inﬂammatory
condition (Das 2001), characterized by elevations in
circulating pro-inﬂammatory cytokines and acute
phase proteins (Mohamed-Ali et al.1 9 9 7 , Visser
et al. 1999, Yudkin et al. 1999, Meier et al. 2002).
Chronic inﬂammation promotes angiogenesis, sustains
cell proliferation, and increases production of free
radicals that cause DNA damage, leading to tumor
initiation and development (Coussens & Werb 2002).
Inﬂammatory processes also play a central role in the
regulation of endometrial mucosa growth and shedding
during the menstrual cycle (Kelly et al. 2001) as well
as in endometrial repair following menstruation
(Salamonsen 2003).
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produced by the liver in response to tissue damage and
inﬂammation. CRP binds to damaged cellular tissues
and components to facilitate phagocytosis and clear-
ance by macrophages and leukocytes (Pasche & Serhan
2004). The major stimulus of CRP synthesis is
interleukin 6 (IL6; Goldman & Liu 1987, Li &
Goldman 1996), which is also responsible for the
recruitment of monocytes during chronic inﬂammation
and therefore plays an important role in the transition
from acute to chronic inﬂammation (Gabay 2006). IL1
receptor antagonist (IL1Ra) is secreted by various
types of cells including immune cells, epithelial cells,
and adipocytes, and is a natural inhibitor of the pro-
inﬂammatory effect of IL1b (Perrier et al. 2006).
Nevertheless, induction of IL1Ra production by other
cytokines and acute phase proteins indicates a possible
role of this cytokine in chronic inﬂammation (Arend
et al. 1998). Moreover, recent studies implicated
IL1Ra in the promotion of type 2 diabetes (Saltevo
et al. 2008, Herder et al. 2009), another well-known
risk factor for endometrial cancer development
(Friberg et al. 2007).
We conducted a case–control study nested within
the European Prospective Investigation into Cancer
and nutrition (EPIC) to examine the relationships
between endometrial cancer risk and blood concen-
trations of CRP, IL6, and IL1Ra. We also investigated
to which extent these inﬂammatory markers can
inﬂuence the association of obesity, endogenous sex
steroids, and C-peptide (a marker of pancreatic insulin
secretion) with endometrial cancer risk. With respect to
endometrial cancer, this is the ﬁrst prospective study of
its kind to date, comprising 305 incident cases and 574
matched controls.
Materials and methods
Study population
The EPIC cohort is a large, multicenter prospective
study, designed to investigate the associations
between nutritional, lifestyle, metabolic, and genetic
risk factors and cancer incidence. It was initiated in
1992 in ten European countries (Denmark, France,
Germany, Greece, Italy, The Netherlands, Norway,
Spain, Sweden, and the United Kingdom) and involved
about 370 000 women and 150 000 men. About
246 000 women and 140 000 men also provided a
blood sample. In the present study, Norway was not
included because blood samples have been collected
only recently, and very few cases of endometrial
cancer have been diagnosed after blood donation.
Study population and baseline data collection have
been previously described in details (Riboli et al.
2002). In brief, questionnaires included data about
dietary, lifestyle and health factors, reproductive
history, use of oral contraceptives (OCs) and hormone
replacement therapy (HRT), history of any disorders or
surgical operations, tobacco smoking and alcohol
consumption, occupational history, physical activity,
and education level.
Collection and storage of blood samples
In France, The Netherlands, the United Kingdom,
Germany, Spain, Italy, and Greece, blood samples
were collected according to a standardized protocol
(Riboli et al. 2002). From each subject, about 30 ml of
blood was drawn, and serum, plasma, erythrocytes, and
buffy coat were aliquoted in plastic straws of 0.5 ml
each, which were heat-sealed and stored under liquid
nitrogen (K196 8C) in a centralized biobank. In
Denmark, blood fractions were aliquoted into 1 ml
tubes, and stored in the vapor phase of liquid nitrogen
containers (K150 8C). In the Swedish center of Umea,
blood samples were divided into ten aliquots of 1.5 ml
each (six plasma, two buffy coat, and two erythro-
cytes), which were rapidly frozen at K80 8Ci n
standard freezers.
Determination of menopausal status at
blood donation
Women were considered as premenopausal when they
reported menstruating regularly over the past 12
months or, if data were incomplete, when they were
!42 years of age at recruitment (99.5% of EPIC
women who had complete data were premenopausal
below age 42). Women were considered as postmeno-
pausal when they reported not having had any menses
over the past12 months, orwhenthey reportedbilateral
ovariectomy. Women who had incomplete data were
considered postmenopausal if they were older than 55.
Women whohadlessthan nine menstrual cycles during
the year preceding recruitment orwomenaged between
42 and 55 years and with missing or incomplete
questionnairedataorwhoreportedtheuseofHRTwere
classiﬁed as having peri-menopausal or unknown
menopausal status and excluded from the analyses.
Follow-up for cancer incidence and vital status
Incident cancer cases were identiﬁed through several
methods, including record linkage with regional cancer
registries (Denmark, Sweden, Italy, The Netherlands,
Spain, and the United Kingdom), health insurance
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follow-up of study subjects (France, Germany, and
Greece). Data on vital status were obtained from
mortality registries at the regional or national level, in
combination with data collected by active follow-up
(Greece). For each EPIC center, closure dates of the
study period were deﬁned as the latest dates of
complete follow-up for both cancer incidence and
vital status (dates varied between centers, from June
1999 to December 2003).
Selection of case and control subjects
Case subjects were selected among women who
developed epithelial endometrial cancer after their
recruitment into the cohort and before the end of the
study period. Cases were coded according to the 10th
revision of the International Statistical Classiﬁcation of
Injuries, Disease, and Deaths. Women whose meno-
pausal status was classiﬁed as peri-menopausal/
unknown or who used any HRT at the time of blood
donation, or any exogenous hormones for contra-
ception or medical purposes, or those with a previous
diagnosis of cancer (except non-melanoma skin
cancer) were excluded from the study. Women whose
endometrial cancers were not primary cancers, or who
had a diagnosis of non-epithelial tumors, or who
reported hysterectomy were also excluded.
A total of 305 incident cases of epithelial endo-
metrial cancer were identiﬁed (80 cases among women
who were premenopausal at blood donation and 225
cases among women who were postmenopausal at
blood donation). The 305 incident cases included 52
cases in Denmark, 49 in Italy, 36 in Spain, 31 in the
United Kingdom, 26 in The Netherlands, 8 in Greece,
13 in France, 18 in Germany, and 72 in Sweden.
For each case subject with endometrial cancer, two
control subjects were chosen at random among
appropriate risk sets consisting of all cohort members
alive and free of cancer (except non-melanoma skin
cancer) at the time of diagnosis of the index case. An
incidence density sampling protocol for control
selection was used, such that controls could include
subjects who became a case later in time, while each
control subject could also be sampled more than once.
Matching characteristics for cases and controls
included study recruitment center, menopausal status
(premenopausal and postmenopausal), age (G6
months) at enrollment, time of the day of blood
collection (G1 h), fasting status (!3 h; 3–6 h, and
O6 h), and, for premenopausal women, phase of
menstrual cycle (‘follicular’, ‘peri-ovulatory’, and
‘luteal’). As described previously (Kaaks et al. 2005),
the menstrual cycle phase was determined using either
backward or forward dating, depending on the study
center. In centers where both dating methods were
used, backward dating was preferred because the
length of the luteal phase of the cycle is generally
more constant than the length of the follicular phase.
With forward dating, the ﬁrst day of a woman’s last
period was set to 0 days, and all subsequent days were
counted sequentially up to a maximum of 39 days.
With backward dating, the ﬁrst day of a woman’s next
period after blood donation was set to 28 days, and the
date on which a blood sample had been provided was
counted backwards from this date to a minimum
acceptable value of K11 days. The follicular phase
corresponds to days 0 to 11 with forward dating and
days K11 to 11 with backward dating; the peri-
ovulatory phase corresponds to days 12 to 16 with both
backward and forward dating; the luteal phase
corresponds to days 17 to 39 with forward dating and
days 17 to 28 with backward dating. For the present
analysis, 574 controls were selected.
All participants had given their consent for their
participation into the EPIC study. The Internal Review
Board of IARC and local institutional review boards in
participating centers have approved the study.
Laboratory assays
Serum (or EDTA plasma for Swedish subjects) from
cases and matched controls was analyzed within the
same analytical batch. CRP and IL6 were measured by
using enzyme-linked immunoassays (R&D Systems
Europe, Lille, France) at the International Agency for
Research on Cancer (Section of Nutrition and
Metabolism), while IL1Ra was measured by bead-
based immunoassay (Linco, Millipore, Billerica, MA,
USA) at the German Cancer Research Center (Division
of Cancer Epidemiology). The different assays were
chosen on the basis of a comparative study that was
published previously (Dossus et al. 2009b).
For quality control, samples from two sera were
analyzed in duplicate within each analytical batch.
Mean intra-batch and inter-batch coefﬁcients of
variation, calculated on the concentrations from the
quality control samples, were 6.8 and 9.3% for CRP,
6.3 and 8.2% for IL6, and 15 and 27.7% for IL1Ra.
Samples from cases and controls, which were matched
together, were analyzed within the same analytical
batch. Twenty-two (2%) CRP and 428 (50%) IL1Ra
values were below the limit of quantiﬁcation. These
values were set to the limit of quantiﬁcation (16 pg/ml
for IL1Ra and 78 ng/ml for CRP). The remaining
missing values (due to problems with analyses or
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of the samples. Less than 2% of the samples had values
above the highest calibration point for each marker.
Owing to these random missing values, CRP was
available for 290 complete matched sets of cases and
controls (i.e. matched sets with CRP levels available
for the case and at least one of the two controls), IL6
for 291, and IL1Ra for 301 complete sets.
Endogenous C-peptide and sex-steroid hormone
measurements were performed on a substantial pro-
portion of the study population (225 complete sets) at
the International AgencyforResearchon Cancer, using
commercially available immunoassays, and have been
described in details elsewhere (Cust et al. 2007, Allen
et al. 2008). In brief, serum testosterone, DHEAS,
androstenedione, estradiol (E2), and estrone (E1) were
measuredbyRIAs(Immunotech,Marseille,Franceand
DSL, Webster, TX, USA), while C-peptide and sex
hormone-binding globulin (SHBG) were measured by
IRMAs (Immunotech and CIS-Bio, Gif-sur-Yvette,
France). Serum E2 levels were measured only in
postmenopausal women because of its large intra-
individual variation during the menstrual cycle among
premenopausal women.
Statistical analyses
In all analyses, measurements of inﬂammatory markers
were transformed using the natural logarithm to
normalize their distributions.
Pearson’s partial correlation coefﬁcients between
inﬂammatory markers and with lifestyle factors were
calculated among controls, adjusting for age at blood
donation (continuous) and laboratory batch. Univariate
associations of baseline characteristics, including BMI
(continuous), age at ﬁrst full-term pregnancy (continu-
ous), number of full-term pregnancies (continuous),
age at menarche (continuous), age at menopause
(continuous), past OC (yes/no) or HRT use (yes/no),
smoking status (never, former, and current smoker),
alcohol consumption (continuous), physical activity
(inactive, moderately inactive, moderately active, and
active), and history of diabetes (yes/no), were
evaluated using conditional logistic regression to retain
the matching.
Odds ratios (ORs) for endometrial cancer in relation
to BMI or circulating inﬂammatory marker levels were
calculated by conditional logistic regression models.
IL6 and CRP were categorized into quartiles, and the
cut-off points were based on the distributions of the
controls. Because about half of the IL1Ra values were
below the limit of quantiﬁcation of the assay, quartiles
could not be used for this marker. Therefore,
undetectable IL1Ra values were grouped in one
category used as the reference category, and values
above the limit of quantiﬁcation were categorized into
tertiles (cut-off points based on the distributions of the
controls with detectable values). BMI was categorized
using the WHO deﬁnition of normal weight
(!25 kg/m
2), overweight (25–29 kg/m
2), and obese
(R30 kg/m
2). Analyses on association between BMI
and endometrial cancer risk included only complete
matching sets (one case and at least one control) with
data on C-peptide, E1, and inﬂammatory markers (258
cases and 452 controls). Likelihood ratio tests were
used to assess linear trends in ORs with assigned
quantitative scores 1, 2, 3, and 4 for the categories. The
effects of potential confounders (additionally to the
matching criteria, controlled for by design) were
examinedbyincludingadditionaltermsintothelogistic
regression models. Potential confounders included
BMI, waist circumference, age at menarche, age at
menopause (among postmenopausal women only),
previous use of OCs, previous use of HRT (among
postmenopausal women only), smoking, alcohol con-
sumption, physical activity, and diabetes. Only BMI
and waist circumference affected point estimates by
more than 10%. Further adjustments for C-peptide,
SHBG,testosterone,DHEAS,androstenedione,E1,and
postmenopausal E2 were also performed.
For analysis of statistical heterogeneity between
study countries or between subgroups of menopausal
status, age at diagnosis, BMI categories, or lag time
between blood donation and diagnosis, ORs were
estimated for continuous measurements of inﬂam-
matory markers transformed on the log2 scale. In this
scale, a unit increase corresponds to a doubling of
concentration. Formal tests of heterogeneity between
the ORs in different EPIC subgroups were based on
c
2-statistics, calculated as the deviations of logistic
b-coefﬁcients observed in each of the subgroups,
relative to the overall b-coefﬁcient.
All statistical tests and corresponding P values were
two-sided, and P values !0.05 were considered
statistically signiﬁcant. All analyses were performed
using the SAS software package (Version 9, SAS
Institute, Cary, NC, USA).
Results
Baseline characteristics of cases and controls are
presented in Table 1. On average, women diagnosed
with endometrial cancer had a higher BMI than
controls (27.5 vs 26.0, P!0.0001), were more often
nulliparous (16.9 vs 7.7%, P!0.0001), were older at
menopause (50.9 vs 49.8 years, PZ0.002), were less
Endocrine-Related Cancer (2010) 17 1007–1019
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more often past HRT users (29.5 vs 16.7%, PZ0.0001)
as reported previously (Dossus et al. 2009a).
Differences in cytokine levels according to baseline
characteristics were evaluated among controls after
adjusting for age at blood donation, laboratory batch,
and BMI. Age at menopause, past HRT and OC use,
self-reported diabetes, physical activity, and alcohol
consumption were not signiﬁcantly associated with any
of the inﬂammatory markers (data not shown).
However, higher CRP and IL6 mean levels were
observed among current smokers (CRP: 1528 ng/ml
and IL6: 1.61 pg/ml) compared to past smokers (CRP:
1066 ng/ml and IL6: 1.38 pg/ml) and never smokers
(CRP: 1066 ng/ml and IL6: 1.22 pg/ml). IL6 mean
levels were also higher in premenopausal women
(1.36 pg/ml) than in postmenopausal women
(1.13 pg/ml). After adjustment for age at blood
donation and laboratory batch, there was a relatively
strong correlation between IL6 and CRP levels
(rZ0.51, 95% conﬁdence interval (CI): 0.44–0.57;
Table 2). Lower degrees of correlation were observed
between IL1Ra and IL6 (rZ0.17, 95% CI: 0.09–0.25)
or between IL1Ra and CRP (rZ0.23, 95% CI:
0.15–0.30). Pearson partial correlations with age at
blood donation varied between 0.10 for IL1Ra (95%
CI: 0.01–0.18), 0.18 for CRP (95% CI: 0.10–0.26), and
0.28 for IL6 (95% CI: 0.20–0.35). All markers were
correlated with BMI (rZ0.37, 95% CI: 0.29–0.44
for CRP; rZ0.32, 95% CI: 0.24–0.39 for IL6; and
rZ0.18, 95% CI: 0.10–0.26 for IL1Ra) and waist
circumference (rZ0.43, 95% CI: 0.35–0.50 for CRP;
rZ0.35, 95% CI: 0.27–0.43 for IL6; and rZ0.24, 95%
CI: 0.15–0.32 for IL1Ra). Scatter plots of BMI by
inﬂammatory marker levels for cases and controls are
presented in Supplementary Figure 1, see section on
supplementary data given at the end of this article.
None of the markers correlated with time before
centrifugation or storage time of the samples (r!0.05,
data not shown).
Conditional logistic regression analyses showed an
increased risk of endometrial cancer with the three
inﬂammatory markers studied, with an OR of 1.58
(95% CI: 1.03–2.41) for the highest versus the lowest
quartile of CRP, 1.66 (95% CI: 1.08–2.54) for the
highest versus the lowest quartile of IL6, and 1.82
Table 1 Baseline characteristics of endometrial cancer cases and matched controls, means (S.D.) or percentages
Variable Cases (NZ305) Controls (NZ574) P
a
Menopausal status Matched
Premenopausal 26.2% 25.1%
Postmenopausal 73.8% 74.9%
Age at blood donation (years) 56.9 (7.3) 57.1 (7.4) Matched
Age at diagnosis (years) 60.4 (7.2) – –
Lag time between blood collection and diagnosis (years) 3.5 (2.6) – –
Body mass index (kg/m
2) 27.5 (5.5) 26.0 (4.3) !0.0001
Obese 26.2% 16.4% 0.0002
Waist circumference (cm) 87.0 (13.1) 83.4 (11.3) !0.0001
Nulliparous 16.9% 7.7% !0.0001
Number of full-term pregnancies
b 2.3 (1.0) 2.4 (1.1) 0.09
Age at ﬁrst full-term pregnancy (years)
b 24.7 (4.2) 24.9 (4.3) 0.96
Age at menarche (years) 13.0 (1.5) 13.3 (1.6) 0.10
Age at menopause (years)
c 50.9 (4.0) 49.8 (3.9) 0.002
Previous OC use 32.8% 42.0% 0.002
Previous HRT use
c 29.5% 16.7% 0.0001
Self-reported diabetes 4.6% 3.7% 0.50
Physical activity 0.64
Inactive 26.4% 27.1%
Moderately inactive 34.6% 37.8%
Moderately active 23.4% 19.5%
Active 15.6% 15.6%
Alcohol consumption (g/day) 7.1 (10.6) 7.3 (10.3) 0.86
Smoking status 0.18
Never smokers 66.5% 60.7%
Former smokers 19.9% 22.3%
Current smokers 13.5% 17.0%
aP values were calculated by using conditional logistic regression.
bAmong parous women only.
cAmong postmenopausal women only.
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category of IL1Ra (Table 3). After adjustment for
BMI, these estimates were lower (from K25% for IL6
to K33% for CRP) and were no longer statistically
signiﬁcant. A similar reduction in risk estimates was
also observed after adjustment for waist circumference
(K19% for IL1Ra and K30% for IL6 and CRP) (data
not shown). Further adjustment for C-peptide resulted
in an additional risk reduction of 6–12%, whereas
further adjustment for E1 only reduced risk estimate by
0–5% (Table 4). In postmenopausal women, we
observed a slightly stronger effect of the adjustment
for E1 on the association between endometrial cancer
and CRP (OR in the highest quartile changed from
1.36, 95% CI: 0.72–2.59 to 1.21, 95% CI: 0.63–2.34)
or IL6 (OR in the highest quartile changed from 1.23,
95% CI: 0.67–2.25 to 1.14, 95% CI: 0.62–2.11).
Very similar estimates were observed after adjustment
for postmenopausal E2 (OR in the highest quartile:
1.23, 95% CI: 0.63–2.40 for CRP and 1.12, 95%
CI: 0.60–2.10 for IL6). Adjustments for testosterone,
androstenedione, DHEAS, or SHBG did not change
risk estimates by more than 5% (data not shown).
Exclusion of subjects with CRP R10 mg/l (a level
indicative of acute inﬂammation) did not affect risk
estimates (data not shown).
Since half of the subjects had values below the limit
of quantiﬁcation for IL1Ra, we performed sensitivity
analyses excluding these subjects. After adjustment for
BMI, ORs were 1.23 (95% CI: 0.61–2.49) for women
in the second tertile and 1.92 (95% CI: 1.02–3.64) for
women in the third tertile compared to women in the
ﬁrst tertile of measured IL1Ra (PtrendZ0.04).
No heterogeneity was observed in the associations
of CRP and IL1Ra with endometrial cancer risk by
country, menopausal status (premenopausal versus
postmenopausal), age at diagnosis (!55 vs R55
years), BMI categories (!25, 25–29, and R30 kg/m
2),
or lag time between blood donation and diagnosis (!2
vs R2 years and !5v sR5 years) (data not shown).
Table 2 Pearson’s partial correlation coefﬁcients (95% conﬁdence interval (CI)) for associations between inﬂammatory factors, body
mass index (BMI), waist circumference, and age at blood donation among controls
CRP IL6 IL1Ra
IL6
a 0.51 (0.44–0.57)
IL1Ra
a 0.23 (0.15–0.30) 0.17 (0.09–0.25)
BMI
a 0.37 (0.29–0.44) 0.32 (0.24–0.39) 0.18 (0.10–0.26)
Waist circumference
a 0.43 (0.35–0.50) 0.35 (0.27–0.43) 0.24 (0.15–0.32)
Age at blood donation
b 0.18 (0.10–0.26) 0.28 (0.20–0.35) 0.10 (0.01–0.18)
aAnalyses on log-transformed data, adjusted for age at blood donation and laboratory batch.
bAnalyses on log-transformed data, adjusted for laboratory batch.
Table 3 Risk (odds ratio, OR (95% conﬁdence interval, CI)) of endometrial cancer by categories of inﬂammatory markers
Categories
1 234 Ptrend
a
CRP
Quartile cut-offs (ng/ml)
b !568 568–1154 1155–2232 O2232
Cases/controls 61/136 65/135 77/136 87/135
Crude (matched) 1.00 1.11 (0.73–1.70) 1.34 (0.89–2.03) 1.58 (1.03–2.41) 0.02
Adjusted for BMI 1.00 0.99 (0.65–1.53) 1.14 (0.74–1.75) 1.05 (0.65–1.69) 0.70
IL6
Quartile cut-offs (pg/ml)
b !0.85 0.85–1.21 1.22–1.89 O1.89
Cases/controls 64/135 57/132 75/133 95/134
Crude (matched) 1.00 0.94 (0.61–1.45) 1.27 (0.83–1.96) 1.66 (1.08–2.54) 0.008
Adjusted for BMI 1.00 0.84 (0.54–1.31) 1.05 (0.67–1.65) 1.24 (0.78–1.98) 0.22
IL1Ra
Category cut-offs (pg/ml)
b %16.0
c 16.1–59.6 59.7–140.7 O140.7
Cases/controls 142/286 33/91 51/91 75/93
Crude (matched) 1.00 0.80 (0.50–1.27) 1.28 (0.83–1.97) 1.82 (1.22–2.73) 0.004
Adjusted for BMI 1.00 0.71 (0.44–1.14) 1.09 (0.70–1.70) 1.44 (0.94–2.21) 0.10
aP value for trend with assigned quantitative scores 1, 2, 3, and 4 for the categories.
bCut-off points were based on the distribution of controls (of subjects with detectable values).
cValues below the limit of quantiﬁcation.
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concentrations among premenopausal women (OR:
1.50, 95% CI: 1.00–2.24) compared to postmenopausal
women (OR: 1.09, 95% CI: 0.88–1.34; Fig. 1). A
similar heterogeneity was observed between cases
diagnosed after or before 2 years following blood
donation (OR: 1.43, 95% CI: 1.00–2.04 for cases
diagnosed !2 years after blood donation and OR:
1.07, 95% CI: 0.86–1.32 for cases diagnosed more than
2 years after blood donation). However, the hetero-
geneity tests were not statistically signiﬁcant
(PheterogeneityZ0.16 and 0.17). Exclusion of cases
diagnosed in the ﬁrst 2 years of follow-up did not
modify the heterogeneity observed by menopausal
status. Similarly, the heterogeneity observed between
early and late diagnosed cases persisted when the
analysis was restricted to postmenopausal women.
An OR of 2.02 (95% CI: 1.26–3.23, PtrendZ0.005)
was observed for obese women (BMI R30 kg/m
2)
compared to normal weight women (BMI !25 kg/m
2;
Table 5). Adjustments for inﬂammatory markers
resulted in reduction of risk estimates by 11% for
CRP, 15% for IL6, and 18% for IL1Ra. After
adjustment for C-peptide, obese women had an OR
of 1.43 (95% CI: 0.86–2.40, PtrendZ0.21) compared to
normal weight women. Adjustment for E1 reduced the
OR for obese versus normal weight women to 1.75
(95% CI: 1.07–2.85, PtrendZ0.03). Further adjustment
for CRP, IL6, or IL1Ra resulted in a reduction in risk
estimates for obese women (K3t oK18%). In the
models adjusted for C-peptide, E1, and inﬂammatory
markers, the ORs for obese versus normal weight
women were close to unity (OR: 1.21, 95% CI:
0.69–2.14 with further adjustment for CRP; OR: 1.16,
95% CI: 0.67–2.01 with further adjustment for IL6;
OR: 1.10, 95% CI: 0.64–1.90 with further adjustment
for IL1Ra). A similar reduction in the estimates was
observed for the risk of endometrial cancer associated
with waist circumference after adjustment for inﬂam-
matory markers, E1, and C-peptide (data not shown).
Discussion
In this prospective study, we observed that circulating
levels of CRP, IL6, and IL1Ra were signiﬁcantly
associated with endometrial cancer risk, although the
association was largely dependent on the levels of
adiposity. The association between adiposity measure-
ments and endometrial cancer was also substantially
attenuated after adjustment for inﬂammatory markers,
even when the effect of C-peptide or E1 was already
taken into account.
Onemechanismfortheinﬂammation-mediatedassoci-
ation between obesity and endometrial cancer could
be the modulation of aromatase activity by cytokines
within the adipose tissue (Purohit & Reed 2002).
Table 4 Risk (odds ratio, OR (95% conﬁdence interval, CI)) of endometrial cancer by categories of inﬂammatory markers, in women
with C-peptide and estrone measurements
Categories
12 3 4 Ptrend
a
CRP
Quartile cut-offs (ng/ml)
b !564 564–1171 1172–2329 O2329
Cases/controls 43/99 54/97 63/99 65/98
Adjusted for BMI 1.00 1.16 (0.71–1.92) 1.25 (0.76–2.06) 1.06 (0.61–1.85) 0.75
Adjusted for BMI and C-peptide 1.00 1.04 (0.62–1.73) 1.07 (0.64–1.79) 0.93 (0.53–1.64) 0.83
Adjusted for BMI and estrone 1.00 1.17 (0.71–1.93) 1.27 (0.77–2.10) 1.01 (0.58–1.77) 0.86
IL6
Quartile cut-offs (pg/ml)
b !0.85 0.85–1.19 1.20–1.80 O1.80
Cases/controls 46/99 45/97 60/99 74/98
Adjusted for BMI 1.00 0.91 (0.55–1.51) 1.16 (0.69–1.97) 1.33 (0.78–2.30) 0.20
Adjusted for BMI and C-peptide 1.00 0.87 (0.52–1.45) 1.06 (0.62–1.82) 1.19 (0.68–2.07) 0.40
Adjusted for BMI and estrone 1.00 0.93 (0.56–1.56) 1.17 (0.69–2.00) 1.30 (0.75–2.25) 0.25
IL1Ra
Category cut-offs (pg/ml)
b %16.0
c 16.1–49.5 49.6–120.2 O120.2
Cases/controls 106/211 24/59 41/61 54/62
Adjusted for BMI 1.00 0.80 (0.45–1.43) 1.24 (0.74–2.06) 1.56 (0.94–2.58) 0.08
Adjusted for BMI and C-peptide 1.00 0.79 (0.44–1.40) 1.10 (0.65–1.86) 1.47 (0.88–2.45) 0.16
Adjusted for BMI and estrone 1.00 0.83 (0.47–1.48) 1.24 (0.74–2.06) 1.56 (0.94–2.60) 0.08
aP value for trend with assigned quantitative scores 1, 2, 3, and 4 for the categories.
bCut-off points were based on the distribution of controls (of subjects with detectable values).
cValues below the limit of quantiﬁcation.
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the ovary has ceased, most of the circulating estrogens
derive from the peripheral aromatase conversion of
androgens in the adipose tissue. It has been shown that
IL6 can stimulate aromatase activity in the adipose tissue
(Zhao et al. 1995) and therefore enhance the estrogen
production and bioavailability. This hypothesis is also
supported by the fact that adjustment for inﬂammatory
markers, in addition to E1, further attenuated the risk
among obese women.
Furthermore, inﬂammatory markers have also been
shown to play an important role in the development of
insulin resistance, hyperglycemia, and type 2 diabetes
(Greenberg & McDaniel 2002), which are known risk
factors for endometrial cancer (Kaaks et al.2 0 0 2 ). IL6
is one of the major cytokines released by the adipose
tissue (Orban et al.1 9 9 9 , Fain et al. 2004). Its
concentration correlates with measures of obesity and
insulin resistance (Yudkin et al. 1999, Vozarova et al.
2001), and with the development of type 2 diabetes
(Pradhan et al. 2001, Spranger et al. 2003, Hu et al.
2004). Moreover, IL6 enhances the hepatic production
of the suppressor of cytokine signaling-3 (a protein that
is known to inhibit the insulin signaling pathway)
(Lebrun & Van 2008) and decreases glucose uptake in
the adipose tissue (Bastard et al. 2002, Feve & Bastard
2009). IL6 is also the main regulatory factor of hepatic
production of CRP, which also decreases insulin
signaling and glucose uptake (Devaraj et al. 2009).
IL1Ra is another cytokine that is released in major
amounts by the adipose tissue (Juge-Aubry et al. 2003)
and is elevated more than sevenfold in obesity (Meier
et al. 2002). More recently, this cytokine has also been
implicated in the development of type 2 diabetes
(Saltevo et al. 2008, Herder et al. 2009). Its role in
obesity-related inﬂammation and in the development
of associated diseases is not yet fully understood.
However, it has been hypothesized that IL1Ra might
have a role in the development of resistance to leptin in
obese patients, and this in turn may further sustain
obesity (Luheshi et al. 1999, Meier et al. 2002). IL1Ra
could also contribute to an increase in adiposity by
inhibiting IL1b, which inhibits lipogenesis on the one
hand, while stimulates lipolysis, glucose transport, and
adipocyte maturation in the adipose tissue on the other
hand (Juge-Aubry et al. 2003).
It is also possible that cytokines have a direct effect
on endometrial carcinogenesis. Within the uterus, IL6
and IL1 are present throughout the menstrual cycle,
with a peak of expression during the proliferative phase
(Kelly et al. 2001, von Wolff et al. 2002). Cytokines
have been shown to enhance the growth and metastasis
of various types of tumors (Aggarwal et al. 2006), and
alterations in the levels of cytokine production have
been reported in several types of cancer, including
gynecologic cancers. For example, increased IL6
concentrations have been reported in patients with
endometrial carcinoma (Chopra et al. 1997, Punnonen
et al. 1998, Bellone et al. 2005, Slater et al. 2006), and
laboratory experiments have demonstrated that nuclear
factor-kB (NF-kB), a cellular transcription factor that
activates genes for immune and inﬂammatory
response, is aberrantly expressed in a majority of
endometrial cancer tumors (Vaskivuo et al. 2002,
Pallares et al. 2004). NF-kB activation also leads to
COX-2 expression, which induces elevated levels of
prostaglandin E2, a protein that has been shown to
promote the transformation of normal endometrium
into neoplastic tissue (Jabbour et al. 2006).
The major strengths of our study are the high degree
of standardization across countries for blood collection
protocols and questionnaire data and the fact that blood
samples were collected prospectively prior to endo-
metrial cancer diagnosis. This design reduces the
possibility of ‘reverse causation bias’, which may
occur when the presence of a tumor modiﬁes
circulating inﬂammatory marker levels. Indeed, the
stronger association observed for IL6 among cases
diagnosed in the 2 years following blood collection
suggests the presence of a preclinical tumor that can
release IL6 (Scambia et al. 1994, Bellone et al. 2005,
Slater et al. 2006) and may have inﬂuenced circulating
levels. However, this was not observed for the
other two markers. Another possible explanation for
0.97–1.37
1.00–2.24 0.16
0.88–1.34
1.00–2.04 0.17
0.86–1.32
0.92–2.20
0.75–1.24
0.96–2.09
95% CI Pheterogeneity Subgroup OR
All women 1.15
Premenopausal 1.50
Postmenopausal 1.09
Lag < 2 years 1.43
Lag > 2 years 1.07
Premenopausal, lag > 2 years 1.42
0.14
Postmenopausal, lag > 2 years 0.97
0.10
Postmenopausal, lag < 2 years 1.42
12
Figure 1 Risk (OR (95% CI)) of endometrial cancer for IL6 on a
continuous log2 scale adjusted for BMI, and stratiﬁed by
menopausal status and lag time to cancer diagnosis.
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follow-up could be that IL6 levels at recruitment may
not be predictive of inﬂammatory status after several
years offollow-up during which major determinants of
IL6 levels such as smoking status, physical activity, or
medical treatments might have changed.
One limitation of our study is that only one cytokine
measurement, at a single point in time, was available to
reﬂect long-term exposure to chronic inﬂammation.
This could result in random misclassiﬁcation, in view
of intra-individual variations over time, and therefore
may have led to underestimation of risk estimates.
However, a recent study measuring cytokine levels in
repeated blood samples taken over a 2-year period
showed moderate to good reliability with correlations
in the range of 0.57–0.92 for the inﬂammatory markers
included in our study (Gu et al. 2009). The latter results
suggest that, while random misclassiﬁcation certainly
occurs, its attenuating effects on risk estimates are
moderate. Another limitation is the fact that about half
of the values for IL1Ra were below the limit of
quantiﬁcation of the assay. Results for this marker
should therefore be considered with caution until
reproduced in other studies.
In conclusion, elevated prediagnostic levels of the
inﬂammatory markers CRP, IL6, and IL1Ra were
associated with an increased risk of endometrial
cancer. Our results provide some degree of support to
the hypothesis that chronic inﬂammation, through its
association with insulin resistance and estrogen
production, but also independently of these two
pathways, might mediate the obesity-related increase
in risk of endometrial cancer, although after adjustment
for BMI the associations were weaker and no longer
statistically signiﬁcant. To our knowledge, this is the
ﬁrst study of its kind, and further prospective studies
are needed to conﬁrm these observations. Further
experimental studies should also investigate whether
inﬂammation has a direct and independent effect on
endometrial carcinogenesis.
Supplementary data
This is linked to the online version of the paper at http://dx.
doi.org/10.1677/ERC-10-0053.
Declaration of interest
The authors declare that there is no conﬂict of interest that
could be perceived as prejudicing the impartiality of the
research reported.
Funding
This work was supported by the Word Cancer Research Fund
(grant number 2007/13). The EPIC study was funded by
‘Europe Against Cancer’ Programme of the European
Commission (SANCO); Ligue contre le Cancer (France);
Socie ´te ´ 3M (France); Mutuelle Ge ´ne ´rale de l’Education
Nationale; Institut National de la Sante ´ et de la Recherche
Table 5 Risk (odds ratio, OR (95% conﬁdence interval, CI)) of endometrial cancer by categories of body mass index (BMI), with
further adjustment for inﬂammatory markers, C-peptide, and estrone
BMI WHO categories (kg/m
2)
!25 25–29 30C Ptrend
a
Cases/controls 81/174 82/151 61/68
Crude (matched) 1.00 1.23 (0.82–1.84) 2.02 (1.26–3.23) 0.005
Adjusted for estrone 1.00 1.14 (0.75–1.72) 1.75 (1.07–2.85) 0.03
Adjusted for C-peptide 1.00 1.02 (0.67–1.56) 1.43 (0.86–2.40) 0.21
Adjusted for C-peptide and estrone 1.00 0.94 (0.61–1.46) 1.24 (0.73–2.12) 0.49
Adjusted for CRP 1.00 1.15 (0.76–1.76) 1.79 (1.06–3.02) 0.04
Adjusted for estrone and CRP 1.00 1.08 (0.70–1.66) 1.57 (0.92–2.69) 0.12
Adjusted for C-peptide and CRP 1.00 1.00 (0.65–1.55) 1.39 (0.80–2.41) 0.29
Adjusted for C-peptide, estrone, and CRP 1.00 0.93 (0.60–1.46) 1.21 (0.69–2.14) 0.57
Adjusted for IL6 1.00 1.14 (0.76–1.73) 1.72 (1.04–2.85) 0.04
Adjusted for estrone and IL6 1.00 1.06 (0.70–1.62) 1.51 (0.90–2.53) 0.15
Adjusted for C-peptide and IL6 1.00 0.99 (0.64–1.52) 1.33 (0.78–2.27) 0.35
Adjusted for C-peptide, estrone, and IL6 1.00 0.92 (0.59–1.43) 1.16 (0.67–2.01) 0.68
Adjusted for IL1Ra 1.00 1.15 (0.76–1.73) 1.65 (1.01–2.71) 0.05
Adjusted for estrone and IL1Ra 1.00 1.07 (0.70–1.62) 1.45 (0.87–2.41) 0.18
Adjusted for C-peptide and IL1Ra 1.00 0.99 (0.64–1.51) 1.26 (0.74–2.14) 0.44
Adjusted for C-peptide, estrone, and IL1Ra 1.00 0.91 (0.59–1.42) 1.10 (0.64–1.90) 0.80
aP value for trend with assigned quantitative scores 1, 2, and 3 for the categories.
L Dossus et al.: Obesity, inﬂammation, and endometrial cancer
www.endocrinology-journals.org 1016Me ´dicale (INSERM); German Cancer Aid; German Cancer
Research Centre; German Federal Ministry of Education and
Research; Danish Cancer Society; ISCIII (RETICC
DR06/0020) of the Spanish Ministry of Health and the
participating regional governments and institutions of
Spain; Cancer Research UK; Medical Research Council,
UK; Hellenic Ministry of Health; Stavros Niarchos
Foundation; Hellenic Health Foundation; Italian Association
for Research on Cancer; Italian National Research Council;
Dutch Ministry of Public Health, Welfare, and Sports; Dutch
Ministry of Health; Dutch Prevention Funds; LK Research
Funds; Dutch ZON (Zorg Onderzoek Nederland); World
Cancer Research Fund (WCRF); Swedish Cancer Society;
Swedish Scientiﬁc Council; Regional Government of Skane,
Sweden; Norwegian Cancer Society.
Acknowledgements
We thank Miss Britta Lederer, Miss Sigrid Henke, and Mr
Thomas Cler for their meticulous work in performing the
immunoassays and Mr David Achaintre for the supervision of
the laboratory work. We also thank the technical support of
the IARC Biological Resource Center for sample retrieval
and processing.
References
Aggarwal BB, Shishodia S, Sandur SK, Pandey MK &
Sethi G 2006 Inﬂammation and cancer: how hot is the
link? Biochemical Pharmacology 72 1605–1621.
(doi:10.1016/j.bcp.2006.06.029)
Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A,
Peeters PH, Onland-Moret NC, Lahmann PH, Berrino F
et al. 2008 Endogenous sex hormones and endometrial
cancer risk in women in the European Prospective
Investigation into Cancer and Nutrition (EPIC).
Endocrine-Related Cancer 15 485–497. (doi:10.1677/
ERC-07-0064)
Arend WP, Malyak M, Guthridge CJ & Gabay C 1998
Interleukin-1 receptor antagonist: role in biology. Annual
Review of Immunology 16 27–55. (doi:10.1146/annurev.
immunol.16.1.27)
Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E,
Grimaldi A, Robert JJ, Capeau J & Hainque B 2002
Adipose tissue IL-6 content correlates with resistance to
insulin activation of glucose uptake both in vivo and
in vitro. Journal of Clinical Endocrinology and
Metabolism 87 2084–2089. (doi:10.1210/jc.87.5.2084)
Bellone S, Watts K, Cane’ S, Palmieri M, Cannon MJ,
Burnett A, Roman JJ, Pecorelli S & Santin AD 2005 High
serum levels of interleukin-6 in endometrial carcinoma
are associated with uterine serous papillary histology, a
highly aggressive and chemotherapy-resistant variant of
endometrial cancer. Gynecologic Oncology 98 92–98.
(doi:10.1016/j.ygyno.2005.03.016)
Calle EE & Kaaks R 2004 Overweight, obesity and cancer:
epidemiological evidence and proposed mechanisms.
Nature Reviews. Cancer 4 579–591. (doi:10.1038/nrc1408)
Chopra V, Dinh TV & Hannigan EV 1997 Serum levels of
interleukins, growth factors and angiogenin in patients
with endometrial cancer. Journal of Cancer Research and
Clinical Oncology 123 167–172. (doi:10.1007/
s004320050045)
Coussens LM & Werb Z 2002 Inﬂammation and cancer.
Nature 420 860–867. (doi:10.1038/nature01322)
Cust AE, Allen NE, Rinaldi S, Dossus L, Friedenreich C,
Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F,
Boutron-Ruault MC et al. 2007 Serum levels of
C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer
risk; results from the European prospective investigation
into cancer and nutrition. International Journal of Cancer
120 2656–2664. (doi:10.1002/ijc.22578)
Das UN 2001 Is obesity an inﬂammatory condition?
Nutrition 17 953–966. (doi:10.1016/S0899-
9007(01)00672-4)
Devaraj S, Singh U & Jialal I 2009 Human C-reactive protein
and the metabolic syndrome. Current Opinion in
Lipidology 20 182–189. (doi:10.1097/MOL.
0b013e32832ac03e)
Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjonneland
A, Olsen A, Overvad K, Clavel-Chapelon F, Fournier A
et al. 2009a Reproductive risk factors and endometrial
cancer: the European prospective investigation into
cancer and nutrition. International Journal of Cancer 127
442–451. (doi:10.1002/ijc.25050)
Dossus L, Becker S, Achaintre D, Kaaks R & Rinaldi S
2009b Validity of multiplex-based assays for cytokine
measurements in serum and plasma from "non-diseased"
subjects: comparison with ELISA. Journal of
Immunological Methods 350 125–132. (doi:10.1016/
j.jim.2009.09.001)
Ehrmann DA, Barnes RB & Rosenﬁeld RL 1995
Polycystic ovary syndrome as a form of functional
ovarian hyperandrogenism due to dysregulation
of androgen secretion. Endocrine Reviews 16
322–353. (doi:10.1210/edrv-16-3-322)
Fain JN, Madan AK, Hiler ML, Cheema P & Bahouth SW
2004 Comparison of the release of adipokines by adipose
tissue, adipose tissue matrix, and adipocytes from visceral
and subcutaneous abdominal adipose tissues of obese
humans. Endocrinology 145 2273–2282. (doi:10.1210/en.
2003-1336)
Feve B & Bastard JP 2009 The role of interleukins in insulin
resistance and type 2 diabetes mellitus. Nature Reviews.
Endocrinology 5 305–311. (doi:10.1038/nrendo.2009.62)
Franks S 1995 Polycystic ovary syndrome. New England
Journal of Medicine 333 853–861. (doi:10.1056/
NEJM199509283331307)
Friberg E, Orsini N, Mantzoros CS & Wolk A 2007 Diabetes
mellitus and risk of endometrial cancer: a meta-analysis.
Diabetologia 50 1365–1374. (doi:10.1007/s00125-007-
0681-5)
Endocrine-Related Cancer (2010) 17 1007–1019
www.endocrinology-journals.org 1017Gabay C 2006 Interleukin-6 and chronic inﬂammation.
Arthritis Research & Therapy 8 (Supplement 2) S3.
(doi:10.1186/ar1917)
Goldman ND & Liu TY 1987 Biosynthesis of human
C-reactive protein in cultured hepatoma cells is induced
by a monocyte factor(s) other than interleukin-1.
Journal of Biological Chemistry 262 2363–2368.
Greenberg AS & McDaniel ML 2002 Identifying the links
between obesity, insulin resistance and beta-cell function:
potential role of adipocyte-derived cytokines in the
pathogenesis of type 2 diabetes. European Journal of
Clinical Investigation 32 (Supplement 3) 24–34.
(doi:10.1046/j.1365-2362.32.s3.4.x)
Gu Y, Zeleniuch-Jacquotte A, Linkov F, Koenig KL, Liu M,
Velikokhatnaya L, Shore RE, Marrangoni A, Toniolo P,
Lokshin AE et al. 2009 Reproducibility of serum
cytokines and growth factors. Cytokine 45 44–49. (doi:10.
1016/j.cyto.2008.10.014)
Herder C, Brunner EJ, Rathmann W, Strassburger K,
Tabak AG, Schloot NC & Witte DR 2009 Elevated
levels of the anti-inﬂammatory interleukin-1 receptor
antagonist precede the onset of type 2 diabetes: the
Whitehall II study. Diabetes Care 32 421–423.
(doi:10.2337/dc08-1161)
Hu FB, Meigs JB, Li TY, Rifai N & Manson JE 2004
Inﬂammatory markers and risk of developing type 2
diabetes in women. Diabetes 53 693–700. (doi:10.2337/
diabetes.53.3.693)
International Agency for Research on Cancer (WHO) 2002
IARC Handbooks of Cancer Prevention. Weight Control
and Physical Activity. Lyon: IARC Press.
Jabbour HN, Sales KJ, Smith OP, Battersby S & Boddy SC
2006 Prostaglandin receptors are mediators of vascular
function in endometrial pathologies. Molecular and
Cellular Endocrinology 252 191–200. (doi:10.1016/j.
mce.2006.03.025)
Juge-Aubry CE, Somm E, Giusti V, Pernin A,
Chicheportiche R, Verdumo C, Rohner-Jeanrenaud F,
Burger D, Dayer JM & Meier CA 2003 Adipose tissue is a
major source of interleukin-1 receptor antagonist:
upregulation in obesity and inﬂammation. Diabetes 52
1104–1110. (doi:10.2337/diabetes.52.5.1104)
Kaaks R, Lukanova A & Kurzer MS 2002 Obesity,
endogenous hormones, and endometrial cancer risk: a
synthetic review. Cancer Epidemiology, Biomarkers &
Prevention 11 1531–1543.
Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C,
Secreto G, Amiano P, Bingham S, Boeing H et al. 2005
Serum sex steroids in premenopausal women and breast
cancer risk within the European Prospective Investigation
into Cancer and Nutrition (EPIC). Journal of the National
Cancer Institute 97 755–765. (doi:10.1093/jnci/dji132)
Kelly RW, King AE & Critchley HO 2001 Cytokine control
in human endometrium. Reproduction 121 3–19. (doi:10.
1530/rep.0.1210003)
Key TJ & Pike MC 1988 The dose–effect relationship
between ’unopposed’ oestrogens and endometrial mitotic
rate: its central role in explaining and predicting
endometrial cancer risk. British Journal of Cancer 57
205–212. (doi:10.1038/bjc.1988.44)
Lebrun P & Van OE 2008 SOCS proteins causing trouble in
insulin action. Acta Physiologica 192 29–36. (doi:10.
1111/j.1748-1716.2007.01782.x)
Li SP & Goldman ND 1996 Regulation of human C-reactive
protein gene expression by two synergistic IL-6 respon-
sive elements. Biochemistry 35 9060–9068. (doi:10.1021/
bi953033d)
Luheshi GN, Gardner JD, Rushforth DA, Loudon AS &
Rothwell NJ 1999 Leptin actions on food intake and body
temperature are mediated by IL-1. PNAS 96 7047–7052.
(doi:10.1073/pnas.96.12.7047)
Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F,
Golay A & Dayer JM 2002 IL-1 receptor antagonist
serum levels are increased in human obesity: a possible
link to the resistance to leptin? Journal of Clinical
Endocrinology and Metabolism 87 1184–1188.
(doi:10.1210/jc.87.3.1184)
Modugno F, Ness RB, Chen C & Weiss NS 2005
Inﬂammation and endometrial cancer: a hypothesis.
Cancer Epidemiology, Biomarkers & Prevention 14
2840–2847. (doi:10.1158/1055-9965.EPI-05-0493)
Mohamed-Ali V,GoodrickS,Rawesh A,KatzDR,MilesJM,
Yudkin JS, Klein S & Coppack SW 1997 Subcutaneous
adipose tissue releases interleukin-6, but not tumor
necrosis factor-alpha, in vivo. Journal of Clinical
Endocrinology and Metabolism 82 4196–4200.
(doi:10.1210/jc.82.12.4196)
Orban Z, Remaley AT, Sampson M, Trajanoski Z &
Chrousos GP 1999 The differential effect of food intake
and beta-adrenergic stimulation on adipose-derived
hormones and cytokines in man. Journal of Clinical
Endocrinology and Metabolism 84 2126–2133.
(doi:10.1210/jc.84.6.2126)
Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M,
Palacios J, Prat J & Matias-Guiu X 2004 Abnormalities in
the NF-kappaB family and related proteins in endometrial
carcinoma. Journal of Pathology 204 569–577. (doi:10.
1002/path.1666)
Pasche B & Serhan CN 2004 Is C-reactive protein an
inﬂammation opsonin that signals colon cancer risk?
Journal of the American Medical Association 291
623–624. (doi:10.1001/jama.291.5.623)
Perrier S, Darakhshan F & Hajduch E 2006 IL-1 receptor
antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
FEBS Letters 580 6289–6294. (doi:10.1016/j.febslet.
2006.10.061)
Pradhan AD, Manson JE, Rifai N, Buring JE & Ridker PM
2001 C-reactive protein, interleukin 6, and risk of
developing type 2 diabetes mellitus. Journal of the
American Medical Association 286 327–334.
(doi:10.1001/jama.286.3.327)
Punnonen R, Teisala K, Kuoppala T, Bennett B &
Punnonen J 1998 Cytokine production proﬁles in the
peritoneal ﬂuids of patients with malignant or benign
L Dossus et al.: Obesity, inﬂammation, and endometrial cancer
www.endocrinology-journals.org 1018gynecologic tumors. Cancer 83 788–796. (doi:10.1002/
(SICI)1097-0142(19980815)83:4!788::AID-
CNCR24O3.0.CO;2-N)
Purohit A & Reed MJ 2002 Regulation of estrogen
synthesis in postmenopausal women. Steroids 67
979–983. (doi:10.1016/S0039-128X(02)00046-6)
Reeves GK, Pirie K, Beral V, Green J, Spencer E & Bull D
2007 Cancer incidence and mortality in relation to body
mass index in the Million Women Study: cohort study.
BMJ 335 1134. (doi:10.1136/bmj.39367.495995.AE)
Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M,
Charrondiere UR, Hemon B, Casagrande C, Vignat J et al.
2002 European Prospective Investigation into Cancer and
Nutrition (EPIC): study populations and data collection.
Public Health Nutrition 5 1113–1124. (doi:10.1079/
PHN2002394)
Salamonsen LA 2003 Tissue injury and repair in the female
human reproductive tract. Reproduction 125 301–311.
(doi:10.1530/rep.0.1250301)
SaltevoJ,LaaksoM,JokelainenJ,Keinanen-KiukaanniemiS,
Kumpusalo E & Vanhala M 2008 Levels of adiponectin,
C-reactive protein and interleukin-1 receptor antagonist
are associated with insulin sensitivity: a population-based
study. Diabetes/Metabolism Research and Reviews 24
378–383. (doi:10.1002/dmrr.831)
ScambiaG,TestaU,PaniciPB,MartucciR,FotiE,PetriniM,
Amoroso M, Masciullo V, Peschle C & Mancuso S 1994
Interleukin-6 serum levels in patients with gynecological
tumors. International Journal of Cancer 57 318–323.
(doi:10.1002/ijc.2910570305)
Slater M, Cooper M & Murphy CR 2006 Human growth
hormone and interleukin-6 are upregulated in
endometriosis and endometrioid adenocarcinoma.
Acta Histochemica 108 13–18. (doi:10.1016/j.acthis.
2006.01.004)
Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann
MM, Ristow M, Boeing H & Pfeiffer AF 2003
Inﬂammatory cytokines and the risk to develop type 2
diabetes: results of the prospective population-based
European Prospective Investigation into Cancer and
Nutrition (EPIC)-Potsdam Study. Diabetes 52 812–817.
(doi:10.2337/diabetes.52.3.812)
Vaskivuo TE, Stenback F & Tapanainen JS 2002 Apoptosis
and apoptosis-related factors Bcl-2, Bax, tumor necrosis
factor-alpha, and NF-kappaB in human endometrial
hyperplasia and carcinoma. Cancer 95 1463–1471.
(doi:10.1002/cncr.10876)
VisserM,BouterLM,McQuillanGM,WenerMH&HarrisTB
1999 Elevated C-reactive protein levels in overweight and
obese adults. Journal of the American Medical Association
282 2131–2135. (doi:10.1001/jama.282.22.2131)
Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C
& Pratley RE 2001 Circulating interleukin-6 in relation to
adiposity, insulin action, and insulin secretion. Obesity
Research 9 414–417. (doi:10.1038/oby.2001.54)
von Wolff M, Stieger S, Lumpp K, Bucking J, Strowitzki T &
Thaler CJ 2002 Endometrial interleukin-6 in vitro is not
regulated directly by female steroid hormones, but by
pro-inﬂammatory cytokines and hypoxia. Molecular
Human Reproduction 8 1096–1102. (doi:10.1093/molehr/
8.12.1096)
World Cancer Research Fund/American Institute for Cancer
Research 2007 Food, Nutrition, Physical Activity, and the
Prevention of Cancer: a Global Perspective. Washington
DC: AICR.
Yudkin JS, Stehouwer CD, Emeis JJ & Coppack SW 1999
C-reactive protein in healthy subjects: associations with
obesity, insulin resistance, and endothelial dysfunction: a
potential role for cytokines originating from adipose
tissue? Arteriosclerosis, Thrombosis, and Vascular
Biology 19 972–978.
Zhao Y, Nichols JE, Bulun SE, Mendelson CR & Simpson ER
1995 Aromatase P450 gene expression in human adipose
tissue. Role of a Jak/STAT pathway in regulation of the
adipose-speciﬁc promoter. Journal of Biological Chemistry
270 16449–16457. (doi:10.1074/jbc.270.27.16449)
Endocrine-Related Cancer (2010) 17 1007–1019
www.endocrinology-journals.org 1019